By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.

The Informed is Root to Rx's deep-dive science track, for when you want to check the work yourself instead of taking the plain-language version on faith. The Plain Talk newsletter covers the same topic in plain language, subscribe at RootToRx.com.

From Issue 016

Issue 016 traced a supplement borrowing a drug's effect under a plant's name. This issue follows the same paradox into a substance with no name on the label at all: peptides sold "for research use only." Last issue, the label was borrowed, a supplement wearing a drug's own mechanism without ever running the drug's trial. This one has no label to borrow at all.

A synthetic peptide sold widely "for research use only," and nicknamed the "wolverine compound" by sellers marketing it for healing. It is not FDA approved for any human use. The human evidence base is thin: five small studies across every use combined, the largest with about 26 subjects, and in the one condition FDA actually reviewed, ulcerative colitis, there is exactly one human trial, reported only as a conference abstract, never published [1]. Its own numbers did not reach statistical significance. No dose-response relationship has been established in any of the four animal studies FDA cited either [2].

BPC-157 sits in a gap, and the gap just got smaller, not closed. The FDA had placed it in a restricted compounding category, then removed it in April 2026 without moving it to the approved list. On July 23, 2026, the FDA's own Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the list of substances a compounding pharmacy can legally prepare for a patient with a prescription [2]. In that same meeting, FDA staff scientists told the committee there is a general lack of quality data supporting the peptide's safety and effectiveness [3]. The vote is non-binding. FDA still has to decide whether to act on it. Translation: a loaded deck committee said yes, the agency's own scientists flagged the evidence gap in the same room, and nothing has actually changed yet.

One detail worth sitting with: the FDA's own review materials scored BPC-157 against a single evaluated use, ulcerative colitis, a chronic gut condition. That is not the joint, tendon, and muscle recovery use driving most of the peptide's popularity. The vote that just happened answered a narrower question than the one most buyers think it answered.

Issue 015 showed you the full label. 016 showed you a borrowed label. This is the blank label. The approved drug you fear carries a warning because someone was legally required to find and print every risk. The peptide you trust carries none because no one ever had to look. The fear didn't make you safer. It moved you to the product with the least oversight.

The Buy Box Problem

Clinical rigor and market winning are not the same contest. Amazon has a named mechanic for this: the Buy Box, the button that actually gets clicked, awarded by an algorithm weighing price, shipping speed, and seller ratings, not which product is clinically best. More than 80 percent of Amazon's sales run through it, and clinical rigor was never one of the inputs [4]. Social media runs the same mechanic without Amazon's name for it. Research on user-generated content consistently finds that peer posts and testimonials move purchase intent largely on their own, independent of whether the underlying claim holds up, because trust and authenticity read as credibility even when they aren't evidence [5].

That is Cherry and Ivy's entire business model from the Black Box Warning this week. The data doesn't have to win. It just has to lose the attention contest to something louder.

Citation Tier Breakdown for Issue 017

Tier 1 — Peer-reviewed, pre-specified: none identified. The only human trial in the reviewed indication is an unpublished conference abstract, not a peer-reviewed paper [2].

Tier 2 — Conference presentation, not yet peer-reviewed: N/A

Tier 3 — Company or institutional press release: FDA 503A compounding category actions and the July 23, 2026 Pharmacy Compounding Advisory Committee vote [2][3]

Tier 4 — Individual case, self-reported: widespread anecdotal/user-reported use, not evidence of safety or efficacy

If you work in clinical research or pharmacy: BPC-157 is a clean teaching example of the gap between regulatory ambiguity ("not yet barred") and regulatory clearance ("approved").

If you are a patient or advocate: a compound with almost no controlled human data carries real unknowns, regardless of how it's marketed.

If you are a general reader: "research use only" is a legal category, not a safety rating. Where to be careful: some sellers cite a single early study or animal findings as if they settle safety. One small study is a start, not a receipt. Ask for the dose, the manufacturer, and who checked.

Skeptic’s Toolkit Applied to This Issue

Get the deck of questions: A Skeptic’s Toolkit — 10 Questions for Any Claim

How many people were studied, and has this been replicated? For BPC-157 in humans, almost none, the evidence is animal data and stories, not trials.

Who is watching after you take it? A prescription drug has a clinician and a monitoring system. A "research use only" peptide has neither.

Does a vote count as evidence? An 8-6 committee vote with one abstention is a split opinion, not a finding. The members who voted no said so on the record: adding it to the list risks signaling a rigor the data doesn't support yet [3].

Does the evidence match the use? The committee's review was scored for ulcerative colitis, using an enema. The recovery and performance claims most buyers care about, in the injectable form most buyers actually use, were outside the scope of what was actually voted on [2].

These 3 issues give you the foundation for everything in this arc.

Issue 003b: How to evaluate any health claim using the Skeptic's Toolkit. Start here.

Issue 001: Why medical distrust is rational, and what to do with it anyway.

Issue 004: How a drug gets from a lab to your pharmacy. The pipeline in plain language.

All back issues are at RootToRx.com.

If this was worth your time, the best thanks is a referral. Series 1 cards are the reward.

Try it yourself: see if you’d have caught this week's Black Box Warning costume on your own.

1)       The Skeptic Type quiz sorts you into your pattern in about two minutes: openlabelmedia.com/skeptic-type.

2)       Got Skepticism? runs any claim through the same one-question move Sam just used.

3)     Stay in the Room shows you how to disagree without a fight so that you can talk to people about these difficult topics.

The quiz and both games play in your browser at openlabelmedia.com, and I would love to see your results on social media!

Instagram: instagram.com/roottorx | Facebook Lab: facebook.com/groups/theroottorxlab | TikTok: tiktok.com/@root.to.rx | YouTube: youtube.com/@roottorx | Threads: threads.com/@roottorx | Subscribe: RootToRx.com

[1] Literature and patent review of BPC-157 preclinical evidence (Pharmaceuticals, 2025). [VERIFY exact citation and confirm no adequate human safety/efficacy trial exists before print.]
[2] FDA Briefing Document for BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (fda.gov/media/193343/download).
[3] Salzman, S. and Kekatos, M. "FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list." ABC News, July 23, 2026.
[4] Amazon Buy Box mechanics and sales share (e.g. Jungle Scout and other e-commerce industry sources), 2024-2026.
[5] Research on user-generated content, trust, and purchase intention in online purchase decisions, summarized 2026.

Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States